Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kerry Harris

Nurse Practitioner, Family Las Cruces, NM Nurse Practitioner

NPI 1164738399 CMS profile 10730481

4351 E Lohman Ave Ste 320, Las Cruces, NM 88011

Open in the dashboard

General payments

$3,116

155 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerry Harris of Las Cruces, NM is reported in the CMS Open Payments database as having received $3,116 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,186 53
2024 General $1,170 52
2023 General $441 29
2022 General $85 6
2021 General $233 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerry Harris
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kerry Harris were reported at $1,186. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kerry Harris Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $233 $124 $35–$379 $132
2022 $85 $141 $44–$430 $149
2023 $441 $154 $49–$476 $160
2024 $1,170 $165 $51–$504 $164
2025 $1,186 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $873 44 payments
  2. Janssen Biotech, Inc. $665 32 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $398 33 payments
  4. Pfizer Inc. $279 12 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $236 10 payments
  6. Phathom Pharmaceuticals, Inc. $228 6 payments
  7. Ardelyx, Inc. $163 6 payments
  8. Madrigal Pharmaceuticals $141 5 payments
  9. RedHill Biopharma Inc. $42 2 payments
  10. Nestle HealthCare Nutrition Inc. $32 2 payments
  11. Other $59 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,930 150 payments
  2. Education $186 5 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $434 22 payments
  2. XIFAXAN $421 34 payments
  3. SKYRIZI Immunology $347 19 payments
  4. STELARA $345 18 payments
  5. TREMFYA $336 15 payments
  6. SKYRIZI Immunology $293 17 payments
  7. VELSIPITY $238 10 payments
  8. ENTYVIO $236 10 payments
  9. IBSRELA $163 6 payments
  10. XELJANZ $126 7 payments
  11. Other $534 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

808

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$119,133

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

45.2%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 17 $59,095
Linzess Linaclotide Brand 45 $37,797
Symproic Naldemedine Tosylate Brand 12 $5,595
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 190 $3,810
Dicyclomine Hcl Generic 84 $2,827
Famotidine Generic 94 $1,841
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 11 $1,796
Pantoprazole Sodium Generic 134 $1,478
Omeprazole Generic 53 $1,225
Lactulose Generic 42 $829

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$19,337

Medicare's payments for the services billed

Medicare patients

248

Average age 71

Services billed

288

143 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 29%
Depression 27%
Ischemic heart disease 25%
Osteoporosis 24%
Chronic kidney disease 19%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $313
$313 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $228
$228 — —
RINVOQ
  • AbbVie, Inc. $150
$150 — —
STELARA
  • Janssen Biotech, Inc. $137
$137 — —
VELSIPITY
  • PFIZER INC. $116
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record